CNBC Stock Blog
- Art Cashin: Caution 'Growing' in Financials, Dividend Moves
- 3 Software Stock Picks from Lazard's Senior Analyst
- Investors Bet on a New Year's Rally For eBay
- Why You Should Play the Reflation Trade: Stock Picker
- S&P to Hit 1,200 by Year-End: Chief Investor
- 5 Big Bank Stocks Investors Should Consider: Strategists
- My 2010 Home Price Outlook: UBS Analyst
- Why Are Options Piling into Dollar Tree?
- Markets Can Rise 5-10% in the Near-Term: Strategist
- Buy These 'Competitively Positioned' Stocks: Portfolio Manager
MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- Garlic Price Rises Surpass Gold, Stocks in China
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Obama Reiterates Commitment to Boost US-India Ties
- Oil Price to Average $75.40 in 2010: Poll
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Consumer Mood Improves, But Anxiety Over Personal Finances
- Jobless Claims Below 500,000, Durable Orders Slip
- Americans Ditch Planes for Trains this Thanksgiving
- Blue Jeans Expected to See Another Green Christmas
- Investors Thankful for Gains This Year
- Thanksgiving & the Markets
- Art Cashin: Caution 'Growing' in Financials, Dividend Moves
- Topless Business Is Taking Off
- 3 Software Stock Picks from Lazard's Senior Analyst
- Schork Oil Outlook: Gas Bulls Pinning Hopes on Mother Nature
- Toyota Makes Recall Fix And So Long Saab
- Investors Bet on a New Year's Rally For eBay
- New-Home Sales Jump to Highest Level in Over Year
- Consumer Mood Improves, But Anxiety Over Finances
- Jobless Claims Below 500,000, Durable Orders Slip
- For Many Americans, a Scaled-Down Holiday Season
- Garlic Price Rises Surpass Gold, Stocks in China
- Judge Erases Couple's $525,000 Mortgage Payment
- Black Friday: Can Banks Tap the Frenzy, Too?
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Seeking Deals, Holiday Fliers Get Early Start
RSS FEED
Text Size 
CNBC News Associate
Dow component Johnson & Johnson—the first major health care company to report earnings this quarter—posted weaker-than-expected quarterly revenue on Tuesday. While the profit topped Wall Street’s forecasts, it was mainly due to cost cuts and lower taxes.
Mike Weinstein, managing director and senior medical technology analyst at JPMorgan shared his analysis.
“They’re in a tough period right now,” Weinstein told CNBC.
“JNJ [JNJ
Loading...
()
] is going through a period in which they’ve had a couple of large products go generic and on top of it, they’re feeling the impact from the economy, which is impacting not only the pharmaceutical business but also the consumer and medical devices business.”
CNBC Data Pages:
Weinstein has a “neutral” rating on Johnson & Johnson.
“The fundamentals right now aren’t there,” he said. “[JNJ’s] going to have to look out beyond the near-term and think more about the longer-term pipeline of the company. There are also concerns out there about health care reform and medical devices excise tax.”
Weinstein also said the health care giant's key brands have seen deceleration in the past few quarters, but consumers will eventually come back in 2010.
What Experts are Saying:
- Health Insurance Rates Will Rise With Baucus Bill: Fratto
- 'Fast Money' Traders: The Obama Health Care Play
______________________________
CNBC Slideshows:
______________________________
______________________________
Johnson & Johnson Competes With:
Eli Lilly [LLY
Loading...
()
]
Novartis [NVS
Loading...
()
]
Procter & Gamble [PG
Loading...
()
]
Intuitive Surgical [ISRG
Loading...
()
]
______________________________
Disclosures:
Weinstein has an investment banking client who owns shares of JNJ. Additionally, a senior executive of JP Morgan is a director at JNJ.
______________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes